GlassScriptPhysician profile
Donald Gene Mack, JR.
NPI 1154498491
$2,719.77
in general payments reported to CMS, 2019-2025
25 companies · $354 in 2025
The $354 reported for 2025 was more than what 88% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $502 · 2020: $135 · 2021: $167 · 2022: $520 · 2023: $573 · 2024: $469 · 2025: $354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,395.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $772.14 | 2022-2025 | Azstarys |
| Pfizer INC. | $301.93 | 2019-2025 | |
| Tris Pharma INC | $277.96 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $263.95 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $188.95 | 2021-2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $158.35 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $114.24 | 2023-2025 | |
| Collegium Pharmaceutical, INC. | $105.73 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $104.12 | 2019-2024 | Gardasil 9, Vaxneuvance, Rotateq |
| Sanofi Pasteur INC. | $72.15 | 2022-2023 | |
| Depuy Synthes Sales INC. | $44.68 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $40.90 | 2023 | Flumist Quadrivalent |
| Shire North American Group INC | $32.12 | 2019 | |
| Neos Therapeutics, LP | $29.90 | 2019 | |
| Glaxosmithkline, LLC. | $26.86 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomerieux INC | $24.74 | 2024 | Biofire Spotfire Respiratory (R) Panel |
| Biomarin Pharmaceutical INC. | $23.31 | 2025 | Voxzogo 1.2mg |
| Aytu Biopharma, INC. | $22.51 | 2020 | |
| Ironwood Pharmaceuticals, INC | $21.98 | 2024 | |
| Global Blood Therapeutics, INC. | $17.90 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $17.43 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $16.58 | 2019 | |
| Adlon Therapeutics L.P. | $16.09 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $12.68 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Mack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.